Clinical Pharmacology of MDA [3,4-methylenedioxyamphetamine]

N/ACompletedNCT00823407

California Pacific Medical Center Research Institute12 enrolled

Overview

The purpose of this study is to investigate the pharmacological and cognitive effects of MDA in healthy humans.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

BASIC_SCIENCE

Masking

DOUBLE

Enrollment

Conditions

Healthy

Interventions

MDADRUG

subjects will receive a single oral dose of MDA 98mg/70kg body weight

PlaceboDRUG

Subjects will receive a single oral dose of placebo

Eligibility

Sex: ALLMin age: 18 YearsMax age: 50 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Healthy males and females age 18-50 * Fluent English speaker * Willing and able to give written consent Exclusion Criteria: * Body mass index \> 30 or \< 18 * Pregnancy or lactation FOR MORE DETAILS CONTACT THE RESEARCH CLINIC.

Locations (1)

CPMC Addiction & Pharmacology Research Laboratory (APRL)

San Francisco, California, United States

Outcomes

Primary Outcomes

MDA will be metabolized to hydroxyamphetamine (HMA) and dihydroxyamphetamine (DHA) and will produce dose-dependent increases in neuroendocrine measures.

Time frame: 0-48 hours post dose

Secondary Outcomes

MDA will produce dose-dependent increases in self-report entactogen-like and stimulant like measures.

Time frame: 0-48 hours post dose

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.